Prot #BGB-11417-101: A Phase 1/1b Open-Label Dose Escalation and Expansion Study of Bcl-2 Inhibitor BGB-11417 in Patients with Mature B-Cell Malignancies

Project: Research project

Project Details

StatusActive
Effective start/end date8/5/218/5/24

Funding

  • DrugDev Inc. (Prot #BGB-11417-101)
  • BeiGene Ltd. (Prot #BGB-11417-101)